Alternatives to Forlong Biotechnology
Forlong Biotechnology is a Biotechnology tool: clinical-stage biotech company developing transformative cytokine therapies. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
Forlong Biotechnology profileMore Biotechnology alternatives
The 20 closest Biotechnology companies to Forlong Biotechnology
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Cellares54BiotechnologySouth San Francisco, USA$327.0MThe first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.
- Website
Verdiva Bio54BiotechnologySan Diego, United States$170.0MClinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.
- Website
Gossamer Bio54BiotechnologySan Diego, USA$150.0MA biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
- Website KHKhartis Therapeutics, Inc.53BiotechnologySan Diego, United States$50.0M
Developing oral small molecule medicines for immunological and chronic diseases.
- Website
Celea Therapeutics53BiotechnologyBoston, USA$360.0MAdvancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).
Showing the 20 closest matches. See the rest on the Forlong Biotechnology profile.
Compare Forlong Biotechnology head to head
Side by side on what each one does, what it costs, and what real users report.